Association between EAT-Lancet diet adherence and cancer incidence/mortality: a systematic review and meta-analysis - Scorecard - MDSpire

Association between EAT-Lancet diet adherence and cancer incidence/mortality: a systematic review and meta-analysis

  • By

  • Xinhe Li

  • Jingqi Chen

  • Zhanqi Sun

  • Minyuan Ni

  • Minmin Fu

  • Yunshi Tang

  • June 1, 2026

  • 0 min

Share

Clinical Scorecard: Link Between Compliance with the EAT-Lancet Diet and Cancer Rates: A Comprehensive Review and Meta-Analysis

At a Glance

CategoryDetail
Condition
Key Mechanisms
Target Population
Care SettingCohort studies only

Key Highlights

  • Add confidence intervals for all HRs.

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

      • S
      • p
      • e
      • c
      • i
      • f
      • y
      • m
      • e
      • t
      • h
      • o
      • d
      • s
      • f
      • o
      • r
      • a
      • s
      • s
      • e
      • s
      • s
      • i
      • n
      • g
      • d
      • i
      • e
      • t
      • a
      • r
      • y
      • a
      • d
      • h
      • e
      • r
      • e
      • n
      • c
      • e
      • .

      Risks

        Patient & Prescribing Data

        Adults aged 18 years and older

        Adherence to the EAT-Lancet diet may lower cancer risk

        Clinical Best Practices

        • subgroup_analyses

        Related Resources & Content

        Original Source(s)

        Association between EAT-Lancet diet adherence and cancer incidence/mortality: a systematic review and meta-analysis

        • by Xinhe Li, Jingqi Chen, Zhanqi Sun, Minyuan Ni, Minmin Fu, Yunshi Tang

        • June 1, 2026

        Related Content

        Case Report: [225Ac]Ac-PSMA-617 therapy in a patient with metastatic castration-resistant prostate cancer (mCRPC) and intracranial meningioma

        Multidimensional exposure architecture shapes vaping-associated transcriptomic dysregulation in oral epithelium

        Evolution of therapeutic paradigms in Hodgkin lymphoma: from “cure-oriented” to “functional cure”